Sean F. Scanlan - 16 May 2023 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Chief Innovation Officer
Signature
/s/ Lisa Taylor as Attorney-in-fact for Sean Scanlan
Issuer symbol
TMCI
Transactions as of
16 May 2023
Net transactions value
-$633,478
Form type
4
Filing time
18 May 2023, 21:00:07 UTC
Previous filing
10 Mar 2023
Next filing
03 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Options Exercise $2,500 +25,000 +77% $0.1000* 57,395 16 May 2023 Direct F1, F2
transaction TMCI Common Stock Sale $635,978 -25,000 -44% $25.44 32,395 16 May 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMCI Stock Option (Right to Buy) Options Exercise $0 -25,000 -43% $0.000000 33,750 16 May 2023 Common Stock 25,000 $0.1000 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 Includes 31,256 RSUs.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.0600 to $25.8000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock option vested in equal annual installments over 4 years, commencing on December 15, 2015 with the last installment vesting on December 15, 2018.